Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 16Other solid neoplasm 9Tumor-Agnostic 3Sarcoma 3Gynecologic 3Gastrointestinal 3Breast 3NET 2Endocrine 2Other hematologic neoplasm 1CNS 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × PM 01183 × Tumor-Agnostic × Clear all
NCT05126433 2025-02-28

JAZZ EMERGE201

Jazz Pharmaceuticals

Phase 2 Terminated
47 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01980667 2017-01-26

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

PharmaMar

Phase 1 Completed
41 enrolled
Tumor-Agnostic

Neoplasms

NCT01970553 2015-04-01

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
47 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡